After Carmot deal, seven clinical oral GLP-1s remain unpartnered

Roche’s acquisition of Carmot takes another oral GLP-1 therapy out of play for large-cap biopharmas looking for an entry point into the obesity race.

On Monday, Roche (SIX:ROG; OTCQX:RHHBY) announced it would acquire privately-held Carmot Therapeutics Inc. for $2.7 billion up front and up to $400 million in milestones. The deal includes preclinical oral small molecule GLP-1 agonist CT-996. ...